These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3988458)

  • 1. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
    Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ
    Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
    Arseneau JC; Schoenfeld DA; Borden EC
    Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of mitoxantrone in head and neck cancer.
    Aapro MS; Alberts DS
    Invest New Drugs; 1984; 2(3):329-30. PubMed ID: 6511239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of mitoxantrone on a daily X 5 schedule.
    Goldsmith MA; Ohnuma T; Jaffrey IH; Greenspan EM; Holland JF
    Am J Clin Oncol; 1984 Oct; 7(5):567-70. PubMed ID: 6507380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
    Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
    Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
    Knight WA; Von Hoff DD; Neidhart JA; Tranum BL; Fabian C; Jones SE
    Invest New Drugs; 1983; 1(2):181-4. PubMed ID: 6678866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone in malignant melanoma.
    Presant CA; Gams R; Bartolucci A
    Cancer Treat Rep; 1984 Jun; 68(6):903-5. PubMed ID: 6733704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
    Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1983 Aug; 6(4):473-6. PubMed ID: 6869318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.
    Alberts DS; Griffith KS; Goodman GE; Herman TS; Murray E
    Cancer Chemother Pharmacol; 1980; 5(1):11-5. PubMed ID: 7460190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
    Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
    Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
    [No Abstract]   [Full Text] [Related]  

  • 12. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
    Bull FE; Von Hoff DD; Balcerzak SP; Stephens RL; Panettiere FJ
    Cancer Treat Rep; 1985 Feb; 69(2):231-3. PubMed ID: 3882233
    [No Abstract]   [Full Text] [Related]  

  • 14. Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
    Mattox DE; Clark GM; Balcerzak SP; O'Bryan RM; Oishi N; Stuckey WJ
    Invest New Drugs; 1984; 2(4):405-7. PubMed ID: 6511243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.
    Sosman JA; Flaherty LE; Liu PY; Fletcher W; Thompson JA; Hantel A; Sondak V
    Invest New Drugs; 1995; 13(1):83-7. PubMed ID: 7499114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
    Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
    Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial with ametantrone (NSC-287513).
    Piccart M; Rozencweig M; Abele R; Cumps E; Dodion P; Dupont D; Kisner D; Kenis Y
    Eur J Cancer Clin Oncol; 1981 Jul; 17(7):775-9. PubMed ID: 7199472
    [No Abstract]   [Full Text] [Related]  

  • 18. Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
    Prentice HG; Wimperis JZ; Robbins G
    Invest New Drugs; 1985; 3(2):207-12. PubMed ID: 3894280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
    Coates AS; Bishop J; Mann GJ; Raghavan D
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of mitoxantrone by 24-hour continuous infusion.
    Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
    Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.